Independent of PD-1, PD-L1, and CTLA4 expression, tumor mutation load (TMB) has been shown in recent years to be a valuable biomarker for predicting the response of PD-1/PD-L1 and CTLA4/B7-1 axis inhibitors in cancer patients treated with ICI. This evidence concerns the gene PDCD1 and neoplasm.